Gelesis Presents Data Showing GS200, The Device That Looks Like A Drug, Treats Obesity
Results of the LIGHT UP study, which included prediabetic and diabetic subjects, could support FDA approval of GS200.
You may also be interested in...
Patients treated with the TransPyloric Shuttle in the 213-patient ENDObesity II trial lost an average of 9.5% of their body-weight and 30.9% of their excess weight.
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 9 - Nov. 15, includes trial data presented at the Veith symposium Nov. 13 - 17 in New York, the American Heart Association Scientific Sessions in Chicago Nov. 10 - 12, and the ObesityWeek meeting in Nashville Nov. 11 - 15.
Danish duo enter pact to discover novel therapeutics for obesity and related metabolic diseases using mechanisms that increase the body's expenditure of energy.